Switch to:
Also traded in: Germany, Italy, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 5.62
CTIC's Cash-to-Debt is ranked lower than
60% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CTIC: 5.62 )
Ranked among companies with meaningful Cash-to-Debt only.
CTIC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.66 Max: No Debt
Current: 5.62
0.01
No Debt
Equity-to-Asset 0.64
CTIC's Equity-to-Asset is ranked higher than
50% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CTIC: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
CTIC' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.7  Med: 0.09 Max: 0.95
Current: 0.64
-2.7
0.95
Debt-to-Equity 0.25
CTIC's Debt-to-Equity is ranked higher than
58% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. CTIC: 0.25 )
Ranked among companies with meaningful Debt-to-Equity only.
CTIC' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.14  Med: 0.06 Max: 14.99
Current: 0.25
-11.14
14.99
Debt-to-EBITDA -0.34
CTIC's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. CTIC: -0.34 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CTIC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.79  Med: -0.38 Max: -0.19
Current: -0.34
-1.79
-0.19
Piotroski F-Score: 2
Altman Z-Score: -33.89
Beneish M-Score: -4.68
WACC vs ROIC
1.27%
465.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -381.34
CTIC's Operating Margin % is ranked lower than
63% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CTIC: -381.34 )
Ranked among companies with meaningful Operating Margin % only.
CTIC' s Operating Margin % Range Over the Past 10 Years
Min: -109780  Med: -440.54 Max: -85.64
Current: -381.34
-109780
-85.64
Net Margin % -361.97
CTIC's Net Margin % is ranked lower than
63% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CTIC: -361.97 )
Ranked among companies with meaningful Net Margin % only.
CTIC' s Net Margin % Range Over the Past 10 Years
Min: -119243.75  Med: -451.38 Max: -90.6
Current: -361.97
-119243.75
-90.6
ROE % -83.91
CTIC's ROE % is ranked lower than
68% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CTIC: -83.91 )
Ranked among companies with meaningful ROE % only.
CTIC' s ROE % Range Over the Past 10 Years
Min: -1010.2  Med: -256.29 Max: -83.91
Current: -83.91
-1010.2
-83.91
ROA % -51.86
CTIC's ROA % is ranked lower than
62% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CTIC: -51.86 )
Ranked among companies with meaningful ROA % only.
CTIC' s ROA % Range Over the Past 10 Years
Min: -261.37  Med: -104.34 Max: -50
Current: -51.86
-261.37
-50
ROC (Joel Greenblatt) % -1935.67
CTIC's ROC (Joel Greenblatt) % is ranked lower than
65% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CTIC: -1935.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CTIC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2837.37  Med: -1789.88 Max: -693.53
Current: -1935.67
-2837.37
-693.53
3-Year Revenue Growth Rate -44.50
CTIC's 3-Year Revenue Growth Rate is ranked lower than
82% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CTIC: -44.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CTIC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -72.3 Max: 283.3
Current: -44.5
0
283.3
3-Year EBITDA Growth Rate 44.50
CTIC's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CTIC: 44.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CTIC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: 32.8 Max: 82.9
Current: 44.5
-39.7
82.9
3-Year EPS without NRI Growth Rate 42.30
CTIC's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CTIC: 42.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CTIC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.7  Med: 32.2 Max: 82.7
Current: 42.3
-24.7
82.7
GuruFocus has detected 2 Warning Signs with CTI BioPharma Corp CTIC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CTIC's 30-Y Financials

Financials (Next Earnings Date: 2019-03-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CTIC Guru Trades in Q3 2017

Jim Simons 411,149 sh (+200.67%)
» More
Q4 2017

CTIC Guru Trades in Q4 2017

Jim Simons 609,849 sh (+48.33%)
» More
Q1 2018

CTIC Guru Trades in Q1 2018

Paul Tudor Jones 25,000 sh (New)
Jim Simons 688,945 sh (+12.97%)
» More
Q2 2018

CTIC Guru Trades in Q2 2018

Pioneer Investments 22,400 sh (New)
Jim Simons 773,445 sh (+12.27%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ROCO:6617, OSTO:BIOA B, ROCO:4167, HKSE:01035, NAS:MLNT, NAS:CALA, TSX:IMV, TSX:FRX, TPE:1720, NAS:ARQL, XTER:VSC, ASX:NEU, NAS:PETX, LSE:VRP, NAS:ADMA, NAS:VSTM, OTCPK:MRMD, NAS:MNKD, ROCO:6497, NAS:ARDX » details
Traded in other countries:CEPS.Germany, CTIC.Italy, 0RLB.UK,
Headquarter Location:USA
CTI BioPharma Corp is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel targeted therapies.

CTI Biopharma Corp is a biopharmaceutical company focused on the development and commercialization of less toxic, more effective cancer therapies. The company's therapeutic area is blood-related cancers. One of the company's products, Pixantrone (PIXUVRI), received conditional marketing approval in the EU in 2012 to treat refractory aggressive B-cell non-Hodgkin lymphoma. Another product is Pacritinib, an oral tyrosine kinase inhibitor to treat mutations such as Janus associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

Ratios

vs
industry
vs
history
PB Ratio 1.68
CTIC's PB Ratio is ranked higher than
82% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CTIC: 1.68 )
Ranked among companies with meaningful PB Ratio only.
CTIC' s PB Ratio Range Over the Past 10 Years
Min: 1.44  Med: 10.32 Max: 100
Current: 1.68
1.44
100
PS Ratio 6.82
CTIC's PS Ratio is ranked higher than
62% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CTIC: 6.82 )
Ranked among companies with meaningful PS Ratio only.
CTIC' s PS Ratio Range Over the Past 10 Years
Min: 0.06  Med: 11.21 Max: 6625.91
Current: 6.82
0.06
6625.91
EV-to-EBIT -0.56
CTIC's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CTIC: -0.56 )
Ranked among companies with meaningful EV-to-EBIT only.
CTIC' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.5  Med: -2.2 Max: -0.2
Current: -0.56
-12.5
-0.2
EV-to-EBITDA -0.56
CTIC's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CTIC: -0.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
CTIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.4  Med: -2.3 Max: -0.2
Current: -0.56
-15.4
-0.2
EV-to-Revenue 1.90
CTIC's EV-to-Revenue is ranked higher than
88% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CTIC: 1.90 )
Ranked among companies with meaningful EV-to-Revenue only.
CTIC' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 20.8 Max: 8846.8
Current: 1.9
0.1
8846.8
Shiller PE Ratio 0.01
CTIC's Shiller PE Ratio is ranked higher than
99% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. CTIC: 0.01 )
Ranked among companies with meaningful Shiller PE Ratio only.
CTIC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.02 Max: 0.04
Current: 0.01
0.01
0.04
Current Ratio 3.58
CTIC's Current Ratio is ranked lower than
52% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CTIC: 3.58 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.48 Max: 24.99
Current: 3.58
0.38
24.99
Quick Ratio 3.58
CTIC's Quick Ratio is ranked higher than
51% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CTIC: 3.58 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.45 Max: 24.96
Current: 3.58
0.38
24.96
Days Inventory 268.50
CTIC's Days Inventory is ranked lower than
91% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CTIC: 268.50 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s Days Inventory Range Over the Past 10 Years
Min: 16.31  Med: 850.7 Max: 8925.18
Current: 268.5
16.31
8925.18
Days Payable 865.83
CTIC's Days Payable is ranked lower than
96% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CTIC: 865.83 )
Ranked among companies with meaningful Days Payable only.
CTIC' s Days Payable Range Over the Past 10 Years
Min: 865.83  Med: 2291.72 Max: 13457.04
Current: 865.83
865.83
13457.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.50
CTIC's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CTIC: -34.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -481.9  Med: -49.4 Max: 0
Current: -34.5
-481.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.99
CTIC's Price-to-Net-Cash is ranked higher than
86% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CTIC: 1.99 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CTIC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.35  Med: 10.07 Max: 680
Current: 1.99
1.35
680
Price-to-Net-Current-Asset-Value 1.92
CTIC's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CTIC: 1.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CTIC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.53  Med: 8.64 Max: 386.76
Current: 1.92
0.53
386.76
Price-to-Tangible-Book 1.67
CTIC's Price-to-Tangible-Book is ranked higher than
86% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CTIC: 1.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CTIC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.46  Med: 6.63 Max: 81.87
Current: 1.67
0.46
81.87
Price-to-Median-PS-Value 0.61
CTIC's Price-to-Median-PS-Value is ranked higher than
73% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CTIC: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CTIC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.17 Max: 707.56
Current: 0.61
0.01
707.56
Earnings Yield (Greenblatt) % -183.21
CTIC's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CTIC: -183.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CTIC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11819.2  Med: -45 Max: -8
Current: -183.21
-11819.2
-8

More Statistics

Revenue (TTM) (Mil) $12.28
EPS (TTM) $ -0.88
Beta-0.59
Volatility81.48%
52-Week Range $1.64 - 5.36
Shares Outstanding (Mil)57.99

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 13 11 11 11
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.78 -1.09 -1.25 -1.46
EPS without NRI ($) -0.78 -1.09 -1.25 -1.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}